Lung Volume Reduction Coils for Emphysema in Alpha-1 Antitrypsin Deficiency

Exclusion Criteria

• •1. Patient has a change in FEV1 \> 20% post-bronchodilator.
• •2. Patients DLCO \< 20% predicted
• •3. Patient has a history of recurrent clinically significant respiratory infection
• •4. Patient has uncontrolled pulmonary hypertension defined by right ventricular pressure \>50mmHg and or evidenced by echocardiogram
• •5. Patient has an inability to walk \>140 meters (150 yards) in 6 minutes
• •6. Patient has evidence of other disease that may compromise survival such as lung cancer, renal failure, etc.
• •7. Patient is pregnant or lactating
• •8. Patient has an inability to tolerate bronchoscopy under moderate sedation or anesthesia
• •9. Patient has clinically significant bronchiectasis
• •10. Patient has giant bullae \> 1/3 lung volume
• •11. Patient has had previous LVR surgery, lung transplant or lobectomy
• •12. Patient has been involved in other pulmonary drug or device studies with 30 days prior to this study
• •13. Patient is taking \> 20mg prednisone (or similar steroid) daily
• •14. Patient is on an antiplatelet agent (such as Plavix) or anticoagulant therapy (such as heparin or coumadin) or has not been weaned off prior to procedure
• •15. Patient has other condition that would interfere with completion of study, follow up assessments or that would adversely affect outcomes
• •16. Patient has severe homogeneous emphysema by CT scan.